Open access
Open access
Powered by Google Translator Translator

Emergency Medicine

CDC Report: Underlying medical conditions and severe illness among 540,667 adults hospitalized with COVID-19, March 2020–March 2021.

5 Jul, 2021 | 02:40h | UTC

Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020–March 2021 – Centers for Disease Control and Prevention

 

Commentary on Twitter

 


Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations.

2 Jul, 2021 | 11:39h | UTC

Vaccine-induced immune thrombotic thrombocytopenia (VITT) – a novel clinico-pathological entity with heterogeneous clinical presentations – British Journal of Haematology

Commentary: Blood clots related to AstraZeneca/Oxford vaccine can be mitigated with early detection – MedicalXpress

 


Delirium in COVID-19: can we make the unknowns knowns?

2 Jul, 2021 | 11:17h | UTC

Delirium in COVID-19: can we make the unknowns knowns? – Intensive Care Medicine

 

Commentary on Twitter

 


Perspective | Why no one is sure if Delta is deadlier – “The variants are spreading faster, but they don’t necessarily have incentive to kill more often”.

1 Jul, 2021 | 09:52h | UTC

Why No One Is Sure If Delta Is Deadlier – The Atlantic

 


AHA Scientific Statement: Managing atrial fibrillation in patients with heart failure and reduced ejection fraction.

1 Jul, 2021 | 09:46h | UTC

Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association – Circulation: Arrhythmia and Electrophysiology

Commentary: The Chicken or the Egg – Atrial Fibrillation and Heart Failure with Reduced Ejection Fraction: Importance of Early AF Treatment – American Heart Association

Top Things to Know: Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction

 

Commentary on Twitter

 


M-A: Simultaneous use of hypertonic saline and IV furosemide for fluid overload – “Benefits of the HSS+Fx over Fx were observed across all examined outcomes in acute decompensated heart failure patients with fluid overload”.

1 Jul, 2021 | 09:41h | UTC

Simultaneous Use of Hypertonic Saline and IV Furosemide for Fluid Overload: A Systematic Review and Meta-Analysis – Critical Care Medicine (link to abstract – $ for full-text)

 


Case Series: Myocarditis following immunization with mRNA COVID-19 vaccines.

30 Jun, 2021 | 10:22h | UTC

Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military – JAMA Cardiology

See also: Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination – JAMA Cardiology

Editorials: Myocarditis Occurring After Immunization With mRNA-Based COVID-19 Vaccines AND Temporal Associations Between Immunization With the COVID-19 mRNA Vaccines and Myocarditis: The Vaccine Safety Surveillance System Is Working

Commentary: More Evidence Links Myocarditis to mRNA COVID-19 Vaccines – TCTMD

Related: CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.

 

Commentary on Twitter

 


Covid: Masks upgrade cuts infection risk, research finds.

30 Jun, 2021 | 10:16h | UTC

Covid: Masks upgrade cuts infection risk, research finds – BBC

 


Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome.

30 Jun, 2021 | 10:13h | UTC

Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome – European Heart Journal

 


Consensus Statement: The role of lung ultrasound in COVID-19 disease.

30 Jun, 2021 | 10:12h | UTC

The role of lung ultrasound in COVID-19 disease – Insights into Imaging

 


Case report: Thrombosis with Thrombocytopenia After the Messenger RNA–1273 Vaccine.

29 Jun, 2021 | 10:07h | UTC

Thrombosis With Thrombocytopenia After the Messenger RNA–1273 Vaccine – Annals of Internal Medicine

Commentary: Expert reaction to case report of from the U.S. of thrombosis with thrombocytopenia after the Moderna mRNA vaccine – Science Media Centre

 


Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – “IVM did not reduce all-cause mortality, length of stay or viral clearance in RCTs in COVID-19 patients with mostly mild disease”.

29 Jun, 2021 | 10:00h | UTC

Ivermectin for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials – Clinical Infectious Diseases

Related: Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

 


EBM Analysis | Does tranexamic acid work for everything? For anything?

29 Jun, 2021 | 09:53h | UTC

Does TXA work for everything? For anything? – First10EM

 


IDSA Updated Covid-19 Guidance: Co-Infection and Antimicrobial Stewardship – “bacterial coinfections with SARS-CoV-2 infection are relatively infrequent (likely occurring in less than 10% of hospitalized COVID-19 patients)”.

28 Jun, 2021 | 09:51h | UTC

Co-Infection and Antimicrobial Stewardship – Infectious Diseases Society of America

Related: Another study shows a high frequency of antibiotic use among patients hospitalized with Covid-19 (85.2%), despite low rates of confirmed secondary bacterial infections.

 


Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department.

28 Jun, 2021 | 09:43h | UTC

Consensus Recommendations on the Treatment of Opioid Use Disorder in the Emergency Department – Annals of Emergency Medicine

 


AASLD Guideline: Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease.

28 Jun, 2021 | 09:33h | UTC

Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases

 


IDSA 2021 focused update guidelines on the management of Clostridioides difficile infection in adults.

25 Jun, 2021 | 10:17h | UTC

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults – Clinical Infectious Diseases

News release: IDSA And SHEA Release New Guidelines for Managing Clostridium Difficile Infection – Infectious Diseases Society of America

 

Commentary on Twitter

 


Perspective | Delta variant triggers dangerous new phase in the pandemic.

24 Jun, 2021 | 10:43h | UTC

Delta variant triggers dangerous new phase in the pandemic – Science

 


CDC: mRNA vaccines are likely linked to cases of myocarditis and pericarditis – 1,226 cases of myocarditis or pericarditis have been reported mostly in people under 30.

24 Jun, 2021 | 09:51h | UTC

CDC safety group says there’s a likely link between rare heart inflammation in young people after Covid shot – CNBC

See also: Experts: mRNA COVID-19 vaccines likely tied to heart inflammation – CIDRAP

Related: Case series: 7 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: clinical and cardiac magnetic resonance imaging findings of 4 cases of myocarditis following mRNA-based COVID-19 vaccination. AND Case series: symptomatic acute myocarditis in 7 adolescents following mRNA COVID-19 vaccination. AND CDC says heart inflammation cases were higher than expected in 16- to 24-year-olds after second Covid vaccine shot, but still rare. AND Israel reports link between rare cases of heart inflammation and COVID-19 vaccination in young men. AND CDC is investigating several reports that teenagers and young adults may have developed myocarditis after receiving mRNA vaccines. Most cases were mild, more often in males than females, more often following dose 2 than dose 1, and typically, within 4 days after vaccination.

 


Review | My Treatment Approach to Clostridioides difficile Infection.

24 Jun, 2021 | 09:47h | UTC

My Treatment Approach to Clostridioides difficile Infection – Mayo Clinic Proceedings

 


[News release – not published yet] COVID-19 outpatient thrombosis prevention trial ends early – “Results suggest that not treating certain symptomatic but stable outpatients with anticoagulant or antiplatelet therapy may be the best course of action”.

23 Jun, 2021 | 10:32h | UTC

NIH ACTIV-4B COVID-19 outpatient thrombosis prevention trial ends earl – Brigham and Women’s Hospital

Commentary: Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b – TCTMD

 


Interactive Infographic | Interpreting a lateral flow SARS-CoV-2 antigen test – “This calculator demonstrates how interpreting a covid-19 lateral flow device (LFD) result varies according to the pre-test probability, and the sensitivity and specificity of the LFD used”.

23 Jun, 2021 | 10:29h | UTC

Interpreting a lateral flow SARS-CoV-2 antigen test – The BMJ

 


Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.

23 Jun, 2021 | 10:25h | UTC

Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia – International Journal of Laboratory Hematology

 


Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.

22 Jun, 2021 | 10:08h | UTC

Ivermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine

Related: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance AND M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials AND FDA: Why you should not use Ivermectin to treat or prevent COVID-19 AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 AND NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” AND Video (5min): Ivermectin for COVID-19 | A Doctor Explains

 


Perspective | COVID-19: The rise and rise of Delta.

22 Jun, 2021 | 10:10h | UTC

COVID-19: The rise and rise of Delta – Sciblogs

 


Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.